Fresenius SE
Home
|
Contacts
|
Imprint
|
Sitemap
|
Glossary
|
Guided Tour
|
German
WHO WE ARE
The Health Care Group
Products and Services
Facts and Figures
Locations Worldwide
Management Board
Supervisory Board
Corporate Governance
Business Development / M&A
Environment
History
Frequently Asked Questions
Contacts
INVESTOR RELATIONS
The Fresenius Shares
Credit Relations
News
Financial Reports
Presentations
Directors' Dealings
Outlook, Facts and Figures
Annual General Meeting
Financial Calendar and Conferences
Information & Order Service
Frequently Asked Questions
Contacts
Stock Dictionary
PRESS
Press Releases
Photo Service
Audio/Video Service
TV Service
Calendar
Facts and Figures
Contacts
HEALTHCARE
Fresenius Medical Care
Dialysis at a Clinic or at Home
Hemodialysis
Peritoneal Dialysis
Supplemental Drugs
Other Extracorporeal Systems
Fresenius Kabi
Infusion Therapy
Clinical Nutrition
Home Care
Fresenius Helios
Care Structure
Medical Quality
Knowledge Management
HELIOS Highlights
Fresenius Vamed
Fresenius Biotech
Transplantation
Cancer Therapy
All Segments
CAREER
Why Fresenius?
Who we are looking for
Job Market
Online application
Career Fairs
Personnel in Numbers
Around our Plants
Contacts
SEARCH
Press Releases
All
Business & Finance
Quarterly Results
Medicine & Research
2010
2009
2008
2007
2006
2005
2004
2003
2002
Order Service
Photo Service
Audio/Video Service
TV Service
Calendar
Facts and Figures
Contacts
Share Price
Next Event
03.08.2010
Business development in Q2 2010
>>>
Further events
>>>
To view PDF-files you need Adobe Reader. You can download this software free of charge.
Medicine & Research - 2003
23.09.2003
Phase I/II study completed successfully: New antibody to treat ovarian cancer patients with symptomatic ascites (fluid accumulation in the abdominal cavity) shown to be well tolerated
Text as PDF-file
17.06.2003
Fresenius grants licence to market immunosuppressive agent ATG in North America
Text as PDF-file
Home
>
Press
>
Press Releases
>
Medicine & Research
>
2003